Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells

Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells

Vγ9Vδ2 T cells represent a promising cancer therapy platform because the implementation of allogenic, off-the-shelf product candidates is possible. However, intravenous administration of human Vγ9Vδ2 T cells manufactured under good manufacturing practice (GMP)-compliant, serum-free conditions are no...

Full description

Bibliographic Details
Main Authors: Kiran K. Parwani, Gianna M. Branella, Rebecca E. Burnham, Andre J. Burnham, Austre Y. Schiaffino Bustamante, Elisabetta Manuela Foppiani, Kristopher A. Knight, Brian G. Petrich, Edwin M. Horwitz, Christopher B. Doering, H. Trent Spencer
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Immunology
Subjects:
gamma delta T cells
gamma delta T cell migration
bone marrow
blood–bone marrow barrier
cancer immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1331322/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1331322/full

Similar Items